Biomarker Heterogeneity in Patients Receiving Lecanemab in the Real World

Masanori Kurihara[1,2*], Ryoko Ihara[1,2], Gen Yoshii[1], Ryosuke Shimasaki[1], Keiko Hatano[1], Taro Bannai[1], Fumio Suzuki[3], Kenji Ishibashi[4], Ko Furuta[5], Katsuya Satoh[6], Aya Midori Tokumaru[3], Kenji Ishii[2,4], Atsushi Iwata[1,2]

1 Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology (TMIG), Tokyo, Japan

2 Integrated Research Initiative for Living Well with Dementia (IRIDE), TMIG, Tokyo, Japan

3 Department of Diagnostic Radiology, TMIG, Tokyo, Japan

4 Research Team for Neuroimaging, TMIG, Tokyo, Japan

5 Department of Psychiatry, TMIG, Tokyo, Japan

6 Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Address correspondence to: Masanori Kurihara

Tokyo Metropolitan Institute for Geriatrics and Gerontology, 35-2, Sakaecho, Itabashi-ku, Tokyo 173-0015, Japan, TEL: 81-3-3964-1141; E-mail: mkurihara-tky@umin.ac.jp

Abstract

Background: While amyloid-β (Aβ) biomarker positivity is sufficient before initiating anti-Aβ antibody therapy, recent revised criteria also highlight the importance of other biomarkers (ATNIVS) to understand heterogeneity in AD.

Design, Setting, and Participants: We reviewed patients who attended our specialty clinic between December 2023 and October 2024. Some participated in tau PET study (^{18}F-MK6240). MRI was assessed using Fazekas score. Remaining samples were analyzed for plasma neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and CSF α-synuclein seed amplification assay (SAA).

Results: During the period, 200 attended and 147 proceeded to screening. Lecanemab was started in 93 of 108 A+ patients; mean age 74.2 years, 73.1% female. While all tested started on lecanemab were positive on amyloid PET, 21% had only regional positivity with lower Aβ burden (centiloid 31.3 ±17.5 vs 67.6 ±20.2) and higher age (79.2 ±5.1 vs 73.3 ±8.9). While all tested had CSF Aβ42/40 values below the single cut-off 0.067 in Japan, three (8.6%) had values close to the cutoff (0.059–0.067), all of whom were all male. Other biomarkers also widely varied from normal to fully abnormal; CSF pTau181 (40.5–168 pg/mL, cut-off 56.5), tau PET-based Braak stage (0–VI), NfL (10.0–103.3 pg/mL), GFAP (121.9–652.5 pg/mL), Fazekas score (0–3), and positive α-synuclein SAA (25–33%). Some associations were indicated including higher Fazekas scores in amyloid PET regional-positive group and higher plasma NfL in CSF Aβ42/40 0.059–0.067 group.

Conclusions: We identified substantial heterogeneity in ATNIVS biomarker profiles among patients receiving lecanemab in a real-world setting.

Introduction

Alzheimer's disease (AD) is a neurodegenerative disease defined by the presence of senile plaques and neurofibrillary tangles (NFT) in the brain, which are aggregates of amyloid β (Aβ) and tau, respectively. Since Aβ aggregation is considered the main upstream factor of AD pathophysiology (1), disease-modifying therapy (DMT) targeting Aβ has been developed and anti-Aβ antibodies lecanemab and donanemab finally proved clinical efficacy in phase 3 trials (2, 3).

After the publication of the phase 3 trial results (2) and the approval from the Food and Drug Administration in the United States (US-FDA), Japan was the second country that approved lecanemab on September 25, 2023 by the Ministry of Health, Labour and Welfare. After coverage by the national health insurance and release of the national optimal use guidelines (OUGs) (4, 5), lecanemab became available in the market on December 20, 2023. We immediately started lecanemab infusion on December 25, 2023. Although most hospitals required more time for preparation, the number of centers prescribing lecanemab has steadily increased in Japan. Lecanemab is now approved in many other countries and unions, including China, Korea, Israel, the United Arab Emirates, the United Kingdom, and the

European Union.

While confirmation of Aβ pathology is sufficient for the initiation of anti-Aβ antibodies in clinical settings, the recent revised criteria highlight the importance of evaluating biological heterogeneity including tau and co-pathologies in research settings (6). In line with the eligibility for anti-Aβantibodies, recently revised criteria for the diagnosis of AD require abnormality in validated core 1 biomarkers including amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) Aβ42/Aβ40 (6). In clinical practice, clinical assessment and positivity of core 1 biomarker is considered sufficient for the diagnosis of symptomatic AD. However, the presence of Aβ biomarker abnormality (≈ Aβ pathology in the brain) increases with age and thus become prevalent in cognitively normal or MCI/dementia due to other causes especially in the older population (7, 8). Therefore, the presence of Aβ biomarker abnormality does not necessarily mean that a patient's cognitive impairment is mainly caused by AD, and therefore clinical judgement is always important (9).

The revised criteria also proposed updated biological staging using tau PET, which would be useful for the understanding of the association between biological and clinical staging (6). While no tau PET tracer is currently covered by the health insurance in Japan so far, continuing research is important to understand the tau PET distribution and concordance/discordance of biological/clinical stating in AD. The revised criteria also updated biomarker categories important in understanding the AD pathophysiological process

known as ATNIVS (A, amyloid; T1, phospho/secreted tau; T2, AD tau proteinopathy; N, neurodegeneration; I, inflammation; V, vascular; and S, α-synuclein (α-syn)). Therefore, although not required for the clinical diagnosis of AD nor required for eligibility assessments for DMT, measurement of these biomarkers in real-world patients receiving lecanemab is important to understand the biological heterogeneity within patients that could affect the disease progression, adverse effects, and clinical efficacy.

Therefore, the aim of this study was to evaluate the heterogeneity in ATNIVS biomarkers in patients receiving lecanemab in the real world.

Methods

Study Population and Design

We reviewed all patients who attended our AD DMT clinic between December 2023 and October 2024. We selected this period in this study that is before modification of our initial screening requirement in November 2024 to include mini-mental state examination (MMSE) 20–21 due to the launch of donanemab on November 26, 2024. The requirement for referral included a diagnosis of mild cognitive impairment (MCI) or mild dementia, MMSE ≥22 (mandatory by Japanese OUGs), no evidence of disease other than AD primarily causing cognitive impairment, and ability to undergo MRI scans. Those interested in the treatment progressed to 3T MRI, clinical dementia rating (CDR; also mandatory by Japanese OUG),

and amyloid PET or CSF biomarker testing.

Ethical Approval and Consent

This study was performed in accordance with the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of the Tokyo Metropolitan Institute for Geriatrics and Gerontology (TMIG) (R23-117). Tokyo Medical Biobank (R21-038), α-syn real-time quaking-induced conversion (RT-QuIC) (R24-032), and ^{18}F-MK6240 PET studies (R22-088) were also approved. Written informed consent was obtained for CSF biomarker measurement, ApoE phenotype testing, biobank, and PET studies.

MRI Protocol and Fazekas score

All MRI images were obtained on the same 3T MRI scanner (Ingenia Elition 3.0T, Koninklijke Philips NV, Amsterdam, the Netherlands). Diffusion-weighted imaging, susceptibility-weighted imaging as well as fluid-attenuated inversion recovery, T2-weighted, and 3D T1-weighted imaging were obtained in accordance with the Japanese guidelines (10). The presence or absence of contraindication including microhemorrhages ≥5, macrohemorrhage, superficial siderosis, or vasogenic edema/sulcal effusion were evaluated by radiologists specialized in neuroradiology, and were also confirmed in a consensus conference. White matter hyperintensities on FLAIR images were scored in the periventricular (PV) and the deep white matter (DWM) using the Fazekas score (11) by an

expert (A.M. Tokumaru). Although not recommended in the appropriate use recommendations from US experts (12), Fazekas score 3 was not an exclusion criterion in the Japanese OUGs and thus lecanemab was initiated after informing the risk if deemed necessary.

Amyloid PET scan and Quantification

All amyloid PET scans conducted during this period used ^{18}F-flutemetamol (Vizamyl®; Nihon Medi-Physics, Tokyo, Japan). Briefly, static emission data were acquired for 90–110 minutes after IV bolus injections. The dose was approximately 185 MBq. Visual reads were conducted by an expert (K. Ishii). According to the approved method, PET images were visually interpreted in five brain regions (parietal, frontal, temporal lobes, striatum, and posterior cingulate cortex/precuneus), and the result was considered positive if there was uptake in any one region. Centiloid scales were calculated using previous reported automated semi-quantitative analysis technique without anatomical images (13) provided in the VIZCalc software (Nihon Medi-Physics). The results of those using previous amyloid PET via approved but different tracers or scanning protocols were re-confirmed to be visually positive by our expert reading but was not included in the quantification analyses.

CSF AD Biomarker Measurement

CSF was obtained via standard lumbar puncture. During the study period in Japan, Aβ42/Aβ40 ratio using the LUMIPULSE system (FUJIREBIO INC., Tokyo, Japan) and its

assays were the only approved CSF assay to confirm eligibility for lecanemab. The CSF concentrations of Aβ42, Aβ40, phosphorylated tau 181 (pTau181), and total tau (tTau) were measured using the LUMIPULSE system and its assays (14, 15) at SRL, Inc. (Tokyo, Japan). Measurements of Aβ42 and Aβ40 were covered by health insurance and those of pTau181 and tTau were by research funding. Predetermined cut-offs were Aβ42/Aβ40 0.067 (15), pTau181 56.5 pg/mL, and tTau 404 pg/mL (14). Although single cutoff of Aβ42/Aβ40 0.067 is used in Japan, US FDA suggests two cutoffs values, and the intermediate range 0.059–0.072 is considered likely-positive range that may be associated with some uncertainties (16). We previously confirmed that CSF pTau181 mildly but significantly increases with Aβ pathology alone (17). However, pTau181 was significantly higher in those with Aβ plus tau pathology (≥ Braak neurofibrillary tangle stage III) and predictive cut-off for Aβ plus tau pathology was 83.1 pg/mL, based on our previous autopsy data and conversion formula between Innotest ELISA and Lumipulse assay (14, 17). Those who consent were tested for ApoE phenotype by isoelectric focusing followed by Western blotting (18). *APOE* testing was not covered by the insurance or was recommended in Japan and was not tested for the remaining patients.

TMIG Biobank

Patients were recruited to our biobank at the first visit to Memory Clinic, before lumbar puncture, or before lecanemab treatment. For those who underwent lumbar puncture,

remaining CSF samples were handled and stored as previously described (14, 19). Blood collection was also conducted and plasma samples were collected in 2Na-EDTA tubes, centrifuged at 2,400×g for 15m within 30 min, and stored at -80 °C for future research.

α-syn Seed Amplification Assay (SAA)

Frozen CSF samples in the biobank which were available on July 19th, 2024 were used for α-syn SAA analyses via RT-QuIC using previously published methods (19). Tester was blinded to any clinical and biomarker information and positivity was determined based on predetermined criteria (19).

Plasma NfL and GFAP measurement

Remaining plasma samples in the biobank were measured for neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP). The measurement was conducted using Simoa HD-X platform and Neurology 2-Plex B multiplex assay (Quanterix, Billerica, MA, USA) at Raybiotech, Inc. (Norcross, GA, USA) after 4-fold dilution. The measurement was conducted in duplication and the averaged concentration was used.

^{18}F-MK6240 PET and Tau PET-based Braak Staging

Emission data were acquired 90-120 minutes following intravenous ^{18}F-MK6240 administration as reported (20). PET images were visually evaluated by two experts (K. Ishibashi and K. Ishii) and PET-based Braak staging was conducted in reference to published methods (21-23) as previously reported (24, 25).

Statistical methods

Statistical analyses were conducted using GraphPad Prism version 9 (GraphPad Software, San Diego, CA, USA) or R version 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria) and a graphical interface EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan) (26). Missing data were handled using a pairwise deletion approach. Categorical variables are expressed as percentages and differences between groups were evaluated using Fisher's exact test. Normally distributed continuous variables are expressed as mean ± standard deviation and differences between groups were tested using the Student's *t*-test or one-way analysis of variance (ANOVA) followed by *post hoc* analyses using Tukey's test. Continuous variables without a normal distribution are expressed as median (interquartile range) and differences between groups were tested using the Mann–Whitney *U* test. Correlation was evaluated using Pearson's method. Receiver Operating Characteristic (ROC) was conducted for centiloid scale and cut-offs were determined as the values that maximized the Youden's index.

Results

Baseline characteristics of the patients receiving lecanemab

During the period, 200 patients attended our DMT clinic and 147 proceeded to further screening. Fourteen already had positive amyloid biomarker results (A+) and seven

screened failed before biomarker testing (i.e. contraindication on MRI, CDR 0). Of the remaining 126, 80 (63%) selected amyloid PET and the remaining selected cerebrospinal fluid (CSF). A+ was confirmed in 74% by PET and 76% by CSF. Thirty-two were non-eligible because of negative amyloid biomarker (A−) and included as control. Of the 108 patients confirmed to be A+, lecanemab was started in 93. Baseline characteristics are summarized in **Table 1**.

Amyloid (A) and Tau (T1, T2) biomarkers

Fifty-three patients had amyloid PET results using flutemetamol at the time of evaluation. While all patients started on lecanemab were positive on amyloid PET, 21% (11/53) had only regional positivity ($A+_{region}$; 1–4 regions) compared to the widespread positive results ($A+_{wide}$; all 5 regions) commonly observed in symptomatic AD. Among the regional group, Aβ deposition was most frequently observed in the frontal lobe followed by temporal lobe and posterior cingulate cortex/precuneus (**Figure 1A**). The mean age was significantly higher in the $A+_{region}$ group compared to the $A+_{wide}$ group (79.2 ±5.1 years vs 73.3 ±8.9 years, p = 0.04). Other baseline characteristics did not differ significantly between groups (**Table 2**). Overall, amyloid burden measured by centiloid scale (0 = young normal, 100 = typical AD dementia) ranged from 3.1 to 112. Centiloid values significantly increased from A−, $A+_{region}$, to $A+_{wide}$ (**Figure 1B**). ROC analysis identified optimal cutoff values of

10.9–20.8 for distinguishing A− vs A+ and 41.5 for $A+_{region}$ vs $A+_{wide}$ (**Figure 1C**).

Although CSF Aβ42/40 was below the cut-off 0.067 in all patients started on lecanemab, the value ranged from 0.027 to 0.063 including three with values close to the cut-off in the likely-positive range by the US FDA (16). All three patients with CSF Aβ42/40 in this range were male. Other baseline characteristics did not differ significantly between groups (**Table 2**).

CSF pTau181 concentration ranged from 40.5 to 168 pg/mL (**Figure 2A**). Using the previously suggested cut-off of 56.5 (14) or normal reference range of 21.5–59.0 pg/mL, CSF pTau181 remained in the normal range in 14.3% (5/35) or 20.0% (7/35), respectively. CSF tTau highly correlated with pTau181 in this population (**Figure 2B**).

Tau PET (T2) using AD-tau specific tracer ^{18}F-MK6240 was conducted in a subset of patients (n = 11). Representative images were previously published (25) or presented in **Figure 2C**. Tau PET-based Braak stage ranged from 0 (none) to □ (max) (**Figure 2D**). Both tau PET and CSF pTau181 results were available in six patients. Although the sample size was small, CSF pTau181 tended to be higher in patients with tau PET-based Braak stage □-□ compared to whom with stage □ (**Figure 2D)**. The association between biological stages based on tau PET and clinical stages widely varied (**Figure 2E**). Five patients with biological > clinical stage tended to be younger in age (70.8 ±8.5 vs 76.7 ±9.1).

Neurodegeneration (N), Inflammation/astrocytic activation (I), and Vascular (V) biomarkers

Plasma NfL (N) ranged from 10.0 to 103.3 pg/mL and did not show significant difference between the A+ and the A− groups (**Figure 3A**). Plasma GFAP (I) ranged from 121.9 to 652.5 pg/mL and was significantly higher than the A− group (**Figure 3B**). Patients were grouped in four quartiles (Q1, Q2, Q3, Q4) for each biomarker. White matter hyperintensities (V) scored by Fazekas score mainly ranged from 0−2 but included some with maximum 3 both for DWM and PV (**Figure 3C**). The association between plasma NfL, plasma GFAP, Fazekas DWM, and Fazekas PV were highly heterogenous (**Figure 3D**).

α-syn (S) biomarker

α-syn SAA (S) was evaluated in 24 with available CSF samples. Six (25%) showed clearly positive results and two (8.3%) showed low positive results. Signs of obvious Lewy body disease (LBD) were screened for all patients with SAA positivity. Only one patient showed signs of LBD (parkinsonism) during the treatment period and the remaining patients showed no signs of LBD, including fluctuating cognition, visual hallucination, REM sleep behavior disorder episode, parkinsonism, hyposmia, lightheadedness on standing, or constipation.

Association between A biomarker characteristics and other TNIVS biomarkers

Although the sample size is small, we also conducted an exploratory analysis comparing TNIVS biomarkers between patients grouped by A biomarker characteristics (**Table 2**). Some associations were indicated including higher Fazekas scores in amyloid PET regional-positive group and higher plasma NfL in CSF Aβ42/40 0.059–0.067 group.

Discussion

We identified substantial heterogeneity in ATNIVS biomarker results in patients receiving lecanemab in the real world.

Baseline characteristics compared to previous reports

Baseline characteristics in this study compared to previous reports (2, 27-32) are summarized in **Table 1**. The mean age (74.2) was slightly higher than those in the phase 3 trial (71.4). This was in line with the baseline data from real-world data from the United States (28, 30, 31) and may suggest older patients are interested in this treatment in a real-world setting. The percentage of patients with MCI, CDR 0.5, or symptomatic drug for AD, and mean values of MMSE score and CDR-SB were very similar to those in the phase 3 trial. These results confirm that the real-world patients receiving lecanemab included in this study has similar disease stage and severity to those in the trial population.

Although it is widely known that women are more prevalent in the general AD population (man: woman approximately 1: 2) (33, 34), men consisted nearly half of the participants in the phase 3 trial (2). While data from some institution showed similar tendency in the real world (28, 32), others reported higher proportion of women (29). In our real-world experience of lecanemab in Japan, the proportion of women were as high as 73.1%. Since women are considered under-represented in clinical trials in general (35), our experience might suggest similar bias in AD trial participants and would further suggest the importance of obtaining real world data.

Although the sample size was small for *APOE* status (37/93), only 32.4% were *APOE* ε4 carrier. This percentage was lower than that of the phase 3 trial (2, 27) or reports from institutions in other countries (**Table 1**) (29, 32, 36). In Japan, there are no boxed warning on the label for *APOE* ε4 homozygotes and during this period, and none declined lecanemab just because of high ARIA risk due to *APOE* ε4 homozygosity. Considering that the percentage in a previous large longitudinal study in Japan was higher (37), larger sample size should be needed to understand the true percentage of *APOE* ε4 carriers in Japanese patients receiving lecanemab in the real world.

Heterogeneity in Core 1 (A, T_1) biomarkers

Amyloid PET burden measured by centiloid scale was lower than those reported in

the global or Asian subpopulation in the phase 3 trial (**Table1**) (2, 27). This difference could be due to number of reasons including difference in PET acquisition, visual interpretation, quantification methods, or population including race. However, we obtained amyloid PET images using ^{18}F-flutemetamol through a standard protocol, visually read according to approved criteria, and centiloid scales were calculated using VIZCalc software that shows constituency with other methods such as CapAIBL or Amyquant (38). While our study included those with low centiloid scales close to 0 that could lower the mean value, the phase 3 Clarity AD trial also included those with low centiloid scale lowest being −16.6 (2). There are uncertainties whether there are racial differences in amyloid PET burden at similar clinical stage. For example, the mean amyloid PET centiloid in the phase 3 trial of donanemab was numerically lower in Japanese (80.8–89.9 centiloid vs. 100.9–103.5 centiloid) (3, 39), although this difference was not observed in the phase 3 trial of lecanemab. Future studies may be warranted to understand the difference of amyloid PET burden in different situations and racial/ethnic groups.

While amyloid PET (A) was visually positive in all tested patients started on lecanemab, the distribution varied as previously reported in research cohorts. Although the majority showed Aβ deposition in all five brain regions in the approved flutemetamol visual read, 21% had only regional positivity ($A+_{region}$). A previous study in a research cohort using similar methods reported prevalence of $A+_{region}$ to be 24% in end-of-life subjects (including

asymptomatic) and 13% in amnestic MCI with amyloid positivity (40). Although these percentages may be similar, there were differences in the distribution. While a previous study reported that the PCC/precuneus was most frequently positive in the $A+_{region}$ group, frontal lobes were most frequently positive in this study, followed by temporal lobes and PCC/precuneus. A different study using flutemetamol but different analytic method reported that the frontal lobe was the most frequent brain region affected (41). Patients in the $A+_{region}$ group were higher in age and tended to have milder clinical stage. These patients may have other different clinical characteristics important in understanding the heterogeneity in AD.

While CSF Aβ42/40 ratio (A) was below the approved cutoff in all tested patients started on lecanemab, some showed values close to the cut-off in the likely-positive range warned by the US FDA. Recent studies have shown that CSF pTau181 is also increased in the presence of brain Aβ pathology, and two of the three patients with CSF Aβ42/40 ratio within this range showed increased pTau181 suggesting AD. However, one patient showed normal pTau181 value. Since also observed in clearly decreased CSF Aβ42/40 ratio, the meaning of normal CSF pTau181 remains to be determined. Our previous autopsy validation study also included patients with normal antemortem CSF pTau181 and advanced brain AD tau pathology at autopsy (17). Conversely, in this study, CSF pTau181 above the cutoff was specific to those with abnormal Aβ42/40 ratio. Although caution is needed for high CSF pTau181 in amyloid-negative patients with some rare diseases (18), our results may suggest

that pTau181 increase is relatively specific for AD in patients evaluated for anti-Aβ antibodies in the real world.

Heterogeneity in Core 2 (T_2) biomarker, tau PET

Recent revised criteria divided tau biomarkers into T1 and T2, and T2 was separated as the core 2 biomarker (6). Tau PET is the most reliable T2 biomarker so far. Although not required for the diagnosis AD, tau PET is suggested to be important for understanding the biological stages of AD (6). In line with the knowledge that the distribution of AD tau pathology follows Braak stage and is associated with clinical severity, four biological stages were proposed using tau PET distribution and uptake (6). ^{18}F-MK6240 is a second-generation tau PET tracer with high sensitivity and specificity against AD tau pathology (42), which has minimal off-target binding to the choroid plexus enabling better evaluation of the medial temporal cortex (43). Tau PET-based Braak stage using this tracer was proposed and have been used in multiple studies (21-23). PET-based Braak stage 0 corresponds to no uptake, and stage I-II corresponds to uptake restricted to the medial temporal areas, both of which may not be directly associated with MCI or dementia stages (6). Although the revised criteria proposed using uptake magnitude in the neocortex to separate the later two stages (moderate vs high uptake), some of the early reports have used topography similar to PET-based Braak stage to approximate the discrimination of these two stages (44).

In this study evaluating patients with MCI or mild dementia due to AD started on lecanemab in the real world, tau PET-based Braak stage ranged from normal (0) to fully abnormal (VI). Three patients (27%) with PET-based Braak stage 0, I, and II were in clinical stages more advanced than those suspected from biological stages, and may suggest the effect of co-pathologies (6). The proportion was in line with recent reports using different tau PET methods (44-46). Five of six patients with PET-based Braak stage V-VI were in the MCI stage. Although we could not determine the cut-off to differentiate moderate versus high tau PET uptake due to limited number of patients so far, some of these five patients may have biological stage more advanced than those suspected from the clinical stage, and may suggest resilience/reserve (6). Continuing research including these evaluations in the real-world patients receiving anti-Aβ antibodies should be important to understand the heterogeneity in disease progression and treatment effect.

While it is now widely known that CSF pTau181 increases with Aβ alone and the revised criteria listed it as a T1 biomarker, many studies have reported that it is also associated with and further increases in the presence of AD tau pathology/PET tracer uptake (17, 23) in A+ individuals. Previous studies have suggested that CSF pTau181 is further increased at Braak stage III-IV but does not continue to increase in later Braak stages (V-VI) and may even decrease in the most advanced stage (Braak VI) (23). Although only limited number of patients had both results for CSF pTau181 and tau PET, patients with PET-based

Braak stage V-VI in this study also tended to have higher CSF pTau181 mostly above our previously estimated cut-off (14, 17). While waiting for better biomarker such as microtubule binding region (MTBR) tau-243 that strongly correlates with AD tau pathology/PET tracer uptake, measuring CSF pTau181 in addition to Aβ42/40 ratio may have additional benefits.

Heterogeneity in NIV biomarkers

Neurodegeneration (N) and Inflammation/astrocytic activation (I) biomarkers are non-specific to AD but are important in AD pathogenesis (6). CSF/plasma NfL and GFAP are the most common fluid biomarkers to access N and I. Cerebrovascular disease is a common and important co-pathology in AD. Although there is no consensus in which indices should be used as a vascular (V) biomarker, white matter hyperintensities (WMH) on MRI are often evaluated and would partly reflect microvascular injuries (6). Fazekas score is a widely used method to score the severity of WMH. High intensities in PV and DWM are separately scored and may have differences in etiology and functional correlates (47). In this study, we identified substantial heterogeneity in N, I, V biomarkers and their combinations. Based on the results of previous studies (6, 48), these biomarkers may become important in understanding the heterogeneity in disease progression speed and other follow up variables in future studies using real world data.

Heterogeneity in S (α-syn) biomarker

Lewy bodies consisting of α-syn is a common co-pathology at autopsy in patients with AD including those with earlier disease onset (49, 50). Now that CSF α-syn SAA is available that is highly specific for Lewy co-pathology, studies have started to test α-syn SAA in patients with AD (50) or in a wider population including AD (51, 52). The positivity has been reported to be 10-30% in patients with AD (19, 50, 53-55) and may associate with higher age, distinct features, and faster progression (52, 56). However, the positive rate in patients receiving lecanemab in the real world was unknown.

In this study, we found that 25-33% of patients receiving lecanemab was α-syn SAA positive using previously validated method (19). The positivity rate was slightly higher than some studies (54, 55) and our previous report (19) but was within reported range. The difference could be due to number of reasons including difference in study population, assay, or its cut-off. However, the fact that the same method yielded lower positivity (10%) in our previous study (19), difference in study population such as higher age (65.2 ±11.6 vs 74.2 ±8.1 years old) may have contributed. Importantly, only 12.5% (1/8) of α-syn SAA positive patients showed clinical signs of LBD. Our results further support the importance of evaluating α-syn SAA even in patients and without obvious symptoms of LBD to understand the biomarker and thus pathological heterogeneity in AD.

Association between A biomarker characteristics and other biomarkers

Although the sample size was small, there were some indications from the exploratory analyses comparing between $A+_{region}$ vs $A+_{wide}$ by amyloid PET and between likely- (0.059−0.067) and clearly- (< 0.059) positive by CSF Aβ42/40 ratio. Fazekas scores (both DWM and PV) were higher in $A+_{region}$. This difference may be explained by vascular factors more often contributing to cognitive symptoms in the $A+_{region}$ group. Fazekas scores tended to be higher in the CSF Aβ42/40 0.059−0.067 group as well. Plasma NfL was higher in the CSF Aβ42/40 0.059−0.067 group. Although the reasons remain unknown, the result may suggest more severe neurodegeneration due to AD or co-pathologies associated with higher plasma NfL.

Although the sample size was very small and there was no significant differences, tau PET-based Braak stage tended to be lower in $A+_{region}$ and CSF Aβ42/40 0.059−0.067 groups. These patients with A biomarker closer to the threshold may tend to have lower tau burden and more co-pathologies contributing to the cognitive symptoms. However, caution is necessary since there have been reports of low amyloid PET high neocortical tau PET cases in the literature (20, 57).

Limitations and future perspectives

There are several limitations to this study. First, this was a retrospective study using

data obtained in clinical setting and there were substantial number of missing results for several biomarkers (especially, T1, T2, and S). Since most patients donated their blood samples to our biobank, future studies using blood-based biomarkers including T1 (i.e. pTau217), T2 (i.e. MTBR-tau243) (58), and S (α-syn SAA) (59) would be important to further understand the biomarker heterogeneity in a larger sample size. Second, this was a single center study in Japan and each institution and each country should have different populations and situations. Larger nationwide or worldwide studies including AD DMT Nationwide Clinical Registry Study by AMED in Japan or ALZ-NET by the Alzheimer's Association would be important to understand the full picture of lecanemab in the real world. Third, we summarized the baseline data and did not include follow-up data in this report, since data collection is ongoing. We plan to report the association between these ATNIVS biomarker heterogeneity and follow-up data (i.e. clinical outcomes and adverse events) as soon as we obtain sufficient data.

Conclusion

We identified substantial heterogeneity in ATNIVS biomarker results in patients receiving lecanemab in the real world. These results would be important to understand the heterogeneity in future analyses using real-world data.

Data Availability Statement

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgments

The authors thank all patients and their family for their participation in our various studies. We also thank members of the Memory Clinic; Department of Neurology/Psychiatry/Nursing/Clinical Psychology/Radiology; Dementia Support Center/ Regional Medical Coordination Office; Healthy Aging Innovation Center (HAIC), TMIG biobank, and the Integrated Research Initiative for Living Well with Dementia (IRIDE) for their assistance.

Fundings

This study was supported by IRIDE of TMIG, fundings from the Tokyo Metropolitan Government to support antibody treatments for dementia/MCI, Translational Research Grant from the TMIG to M.K., KAKENHI from the Japan Society for the Promotion of Science (JSPS) to M.K. (JP23K14789), R.I. (JP24K10653), and K.S. (JP21K07417), and AMED grant to A.I. (JP24he2202020).

Conflict of Interest

MK received honoraria for lectures from Eisai, Eli Lilly; patent assignment fee from FUJIREBIO; and research support from Nihon Medi-Physics. RI received advisory fees from

Eisai, Eli Lilly and MSD; consultant fee from Chugai; and honoraria for lectures from Eisai, Eli Lilly, Nihon Medi-Physics, PDR Pharma, FUJIREBIO, Sysmex and IQVIA. TB received honoraria for lectures from Eisai. KF received honoraria for lectures from Eisai and Eli Lilly. AMT received honoraria for lectures from Eisai and Eli Lilly. K. Ishii received research grant from Nihon Medi-Physics; advisory fees, honoraria for lectures and research grants from Eli Lilly, Nihon Medi-Physics and PDR Pharma.

AI received research grants from Eisai, FUJIREBIO, Janssen pharma, Sysmex, Kobayashi Pharma, Eli Lilly, Fujifilm, SONY, Biogen and Chugai/Roche; advisory fees from Eisai, FUJIREBIO, Eli Lilly, Roche, GSK, Otsuka, Soundwave Innovation; honoraria for lectures from Eisai, Eli Lilly, Biogen, Chugai/Roche, HU frontier, FUJIREBIO, Kowa, Sysmex, Ono, Otsuka, Alnylam, Daiichi Sankyo, Tokio Marine & Nichido Fire Insurance, PDR pharma, IQVIA, Sumitomo Pharma, MSD, Janssen pharma, and Kyowa Kirin; patent assignment fee from FUJIREBIO; and is involved in post marketing surveillance of lecanemab in Japan. Other authors report no disclosures associated with the content of this manuscript.

References

1. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595-608.

2. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21.

3. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512-27.
4. Japanese Ministry of Helath Labour and Welfare. Optimal use promotion guideline: lecanemab (genetical recombination) 2023 [Available from: https://www.pmda.go.jp/files/000265885.pdf.
5. Iwata A. How will the emergence of lecanemab change dementia treatment? Geriatr Gerontol Int. 2024;24(9):841-4.
6. Jack CR, Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024;20(8):5143-69.
7. Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939-49.
8. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924-38.
9. Bergeron D, Ossenkoppele R, Jr Laforce R. Evidence-based Interpretation of Amyloid-beta PET Results: A Clinician's Tool. Alzheimer Dis Assoc Disord. 2018;32(1):28-34.
10. Kakeda S, Miki Y, Kudo K, Mori H, Tokumaru AM, Abe O, et al. Practical brain MRI guidelines for anti-Abeta antibody treatment in early symptomatic Alzheimer's disease. Jpn J Radiol. 2025.
11. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351-6.
12. Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2023;10(3):362-77.
13. Imabayashi E, Tamamura N, Yamaguchi Y, Kamitaka Y, Sakata M, Ishii K. Automated semi-quantitative amyloid PET analysis technique without MR images for Alzheimer's disease. Ann Nucl Med. 2022;36(10):865-75.
14. Kurihara M, Kondo S, Ohse K, Nojima H, Kikkawa-Saito E, Iwata A. Relationship Between Cerebrospinal Fluid Alzheimer's Disease Biomarker Values Measured via Lumipulse Assays and Conventional ELISA: Single-Center Experience and Systematic Review. J Alzheimers Dis. 2024;99(3):1077-92.
15. Nojima H, Ito S, Kushida A, Abe A, Motsuchi W, Verbel D, et al. Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE((R)) system. Ann Clin Transl Neurol. 2022;9(12):1898-909.

16. FDA. EVALUATION OF AUTOMATIC CLASS Ill DESIGNATION FOR Lumipulse G β-Amyloid Ratio (1-42/1-40) [July 31, 2023].
17. Kurihara M, Matsubara T, Morimoto S, Arakawa A, Ohse K, Kanemaru K, et al. Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and Abeta42 in Alzheimer's disease and other neurodegenerative diseases. Acta Neuropathol Commun. 2024;12(1):48.
18. Kurihara M, Komatsu H, Sengoku R, Shibukawa M, Morimoto S, Matsubara T, et al. CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease. Neurology. 2023;100(10):e1009-e19.
19. Kurihara M, Satoh K, Shimasaki R, Hatano K, Ohse K, Taira K, et al. alpha-synuclein seed amplification assay sensitivity may be associated with cardiac MIBG abnormality among patients with Lewy body disease. NPJ Parkinsons Dis. 2024;10(1):190.
20. Shimasaki R, Kurihara M, Ishibashi K, Tokumaru AM, Ishii K, Iwata A. Diagnostic Challenge in Frontal Variant Alzheimer's Disease With Low Amyloid-beta PET Retention. Ann Clin Transl Neurol. 2025;12(7):1506-10.
21. Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143(9):2818-30.
22. Pascoal TA, Benedet AL, Tudorascu DL, Therriault J, Mathotaarachchi S, Savard M, et al. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. Brain. 2021;144(11):3517-28.
23. Therriault J, Pascoal TA, Lussier FZ, Tissot C, Chamoun M, Bezgin G, et al. Biomarker modeling of Alzheimer's disease using PET-based Braak staging. Nat Aging. 2022;2(6):526-35.
24. Ishibashi K, Kurihara M, Toyohara J, Ishii K, Iwata A. Pitfalls of Amyloid-Beta PET: Comparisons With 18 F-MK-6240 and 18 F-THK5351 PET. Clin Nucl Med. 2024;49(4):319-21.
25. Ishibashi K, Kurihara M, Ihara R. Both Amyloid and Tau Assessments Are Desired Before Initiating Disease-modifying Therapy for Alzheimer Disease: Three Real-world Cases. Clin Nucl Med. 2025;50(8):806-7.
26. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452-8.
27. Chen C, Katayama S, Lee JH, Lee JY, Nakagawa M, Torii K, et al. Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease. J Prev Alzheimers Dis. 2025;12(5):100160.
28. Paczynski M, Hofmann A, Posey Z, Gregersen M, Rudman M, Ellington D, et al. Lecanemab Treatment in a Specialty Memory Clinic. JAMA Neurol. 2025;82(7):655-65.
29. Shields LBE, Hust H, Cooley SD, Cooper GE, Hart RN, Dennis BC, et al. Initial

Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center. J Prev Alzheimers Dis. 2024;11(6):1549-62.
30. Sabbagh MN, Zhao C, Mahendran M, Jang SR, Laliberte F, Toyosaki H, et al. Characterizing the Journey of Early Alzheimer's Disease in Patients Initiating Lecanemab Treatment in the United States: A Real-World Evidence Study. Neurol Ther. 2025;14(3):1115-27.
31. Mittler B, Cambi X, Biskach M, Reisman J, Wang Y, Berlowitz D, et al. Patient journey and decision processes for anti-amyloid therapy in Alzheimer's disease. J Neurol. 2025;272(5):341.
32. Bregman N, Nathan T, Shir D, Omer N, Levy MH, David AB, et al. Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease. Alzheimers Res Ther. 2025;17(1):119.
33. Ferretti MT, Iulita MF, Cavedo E, Chiesa PA, Schumacher Dimech A, Santuccione Chadha A, et al. Sex differences in Alzheimer disease - the gateway to precision medicine. Nat Rev Neurol. 2018;14(8):457-69.
34. Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060). Alzheimers Dement. 2021;17(12):1966-75.
35. Corneli A, Hanlen-Rosado E, McKenna K, Araojo R, Corbett D, Vasisht K, et al. Enhancing Diversity and Inclusion in Clinical Trials. Clin Pharmacol Ther. 2023;113(3):489-99.
36. Paczynski M, Hofmann A, Posey Z, Gregersen M, Rudman M, Ellington D, et al. Lecanemab Treatment in a Specialty Memory Clinic. JAMA Neurol. 2025.
37. Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, et al. Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. Alzheimers Dement. 2018;14(8):1077-87.
38. Shang C, Sakurai K, Nihashi T, Arahata Y, Takeda A, Ishii K, et al. Comparison of consistency in centiloid scale among different analytical methods in amyloid PET: the CapAIBL, VIZCalc, and Amyquant methods. Ann Nucl Med. 2024;38(6):460-7.
39. Sato S, Hatakeyama N, Fujikoshi S, Katayama S, Katagiri H, Sims JR. Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial. Neurol Ther. 2024;13(3):677-95.
40. Farrar G, Molinuevo JL, Zanette M. Is there a difference in regional read [(18)F]flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment? Eur J Nucl Med Mol Imaging. 2019;46(6):1299-308.
41. Collij LE, Salvado G, Wottschel V, Mastenbroek SE, Schoenmakers P, Heeman F, et al. Spatial-Temporal Patterns of beta-Amyloid Accumulation: A Subtype and Stage Inference Model Analysis. Neurology. 2022;98(17):e1692-e703.

42. Aguero C, Dhaynaut M, Normandin MD, Amaral AC, Guehl NJ, Neelamegam R, et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun. 2019;7(1):37.
43. Gogola A, Minhas DS, Villemagne VL, Cohen AD, Mountz JM, Pascoal TA, et al. Direct Comparison of the Tau PET Tracers (18)F-Flortaucipir and (18)F-MK-6240 in Human Subjects. J Nucl Med. 2022;63(1):108-16.
44. Pichet Binette A, Smith R, Salvado G, Tideman P, Glans I, van Westen D, et al. Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease. JAMA Neurol. 2025;82(7):666-75.
45. Mendes AJ, Ribaldi F, Pievani M, Boccalini C, Garibotto V, Frisoni GB, et al. Validating the Amyloid Cascade Through the Revised Criteria of Alzheimer's Association Workgroup 2024 for Alzheimer Disease. Neurology. 2025;104(11):e213675.
46. Lu J, Wang J, Wu J, Zhang H, Ma X, Zhu Y, et al. Pilot implementation of the revised criteria for staging of Alzheimer's disease by the Alzheimer's Association Workgroup in a tertiary memory clinic. Alzheimers Dement. 2024;20(11):7831-46.
47. Kim KW, MacFall JR, Payne ME. Classification of white matter lesions on magnetic resonance imaging in elderly persons. Biol Psychiatry. 2008;64(4):273-80.
48. Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66-77.
49. Beach TG, Malek-Ahmadi M. Alzheimer's Disease Neuropathological Comorbidities are Common in the Younger-Old. J Alzheimers Dis. 2021;79(1):389-400.
50. Tosun D, Hausle Z, Iwaki H, Thropp P, Lamoureux J, Lee EB, et al. A cross-sectional study of alpha-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function. Alzheimers Dement. 2024;20(8):5114-31.
51. Palmqvist S, Rossi M, Hall S, Quadalti C, Mattsson-Carlgren N, Dellavalle S, et al. Cognitive effects of Lewy body pathology in clinically unimpaired individuals. Nat Med. 2023;29(8):1971-8.
52. Quadalti C, Palmqvist S, Hall S, Rossi M, Mammana A, Janelidze S, et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat Med. 2023;29(8):1964-70.
53. Bellomo G, Toja A, Paolini Paoletti F, Ma Y, Farris CM, Gaetani L, et al. Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay. Alzheimers Dement. 2024;20(4):2444-52.
54. Pichet Binette A, Mammana A, Wisse L, Rossi M, Strandberg O, Smith R, et al. Associations between misfolded alpha-synuclein aggregates and Alzheimer's disease pathology in vivo. Alzheimers Dement. 2024;20(11):7624-34.

55. Levin J, Baiardi S, Quadalti C, Rossi M, Mammana A, Voglein J, et al. alpha-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden. Alzheimers Dement. 2024;20(6):4351-65.
56. Tosun D, Hausle Z, Thropp P, Concha-Marambio L, Lamoureux J, Lebovitz R, et al. Association of CSF alpha-synuclein seed amplification assay positivity with disease progression and cognitive decline: A longitudinal Alzheimer's Disease Neuroimaging Initiative study. Alzheimers Dement. 2024;20(12):8444-60.
57. Krishnadas N, Dore V, Laws SM, Porter T, Lamb F, Bozinovski S, et al. Exploring discordant low amyloid beta and high neocortical tau positron emission tomography cases. Alzheimers Dement (Amst). 2022;14(1):e12326.
58. Horie K, Salvado G, Koppisetti RK, Janelidze S, Barthelemy NR, He Y, et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease. Nat Med. 2025;31(6):2044-53.
59. Okuzumi A, Hatano T, Matsumoto G, Nojiri S, Ueno SI, Imamichi-Tatano Y, et al. Propagative alpha-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med. 2023;29(6):1448-55.

A

								91%	73%	73%	45%	36%
Age	Sex	Clinical stage	MMSE	CDR	CDR-SB	CL	Positive Regions	Frontal	Temporal	PCC/Precuneus	Parietal	Striatum
81-85	F	MCI	24	0.5	2	3.1	1	0	1	0	0	0
71-75	F	MCI	28	0.5	1	20.8	2	1	1	0	0	0
76-80	F	dementia	23	1	4.5	7.8	3	1	1	1	0	0
71-75	F	MCI	24	0.5	3	24.1	3	1	1	1	0	0
76-80	F	MCI	26	1	5	35.4	3	1	0	0	1	1
81-85	F	MCI	25	0.5	1.5	54.2	3	1	0	1	1	0
71-75	F	dementia	23	0.5	4.5	26.4	4	1	1	1	0	1
86-90	M	MCI	26	0.5	1.5	32.3	4	1	1	1	1	0
86-90	F	MCI	25	0.5	2	39.2	4	1	1	1	1	0
76-80	F	MCI	27	0.5	2.5	40.4	4	1	1	1	0	1
71-75	F	MCI	30	0.5	2	60.6	4	1	0	1	1	1



Figure 1. Regional amyloid PET positivity and centiloid scales of amyloid-positive patients on lecanemab (n = 53) and amyloid-negative patients (n = 21)

A) Characterstics of 11 patient with regional (1–4 of 5) amyloid positivity. All patients were 72 or older in age and amyloid deposition was most frequently observed in the frontal lobe followed by temporal lobe and posterior cingulate cortex/precuneus. B) Representative amyloid PET images of $A+_{wide}$ and $A+_{region}$. While Aβ deposition is observed in all five regions in $A+_{wide}$, deposition was observed only in three regions (frontal, temporal, and PCC/precuneus in this case) in $A+_{region}$. C) Centiloid scale significantly increased from A− (-4.6 ±10.7), $A+_{region}$ (31.3 ±17.5), to $A+_{wide}$ (67.6 ±20.2). D) ROC curves differentiating A− vs A+ or $A+_{region}$ vs $A+_{wide}$. Centiloid scale had high AUC for both differentiations.

A−, amyloid negative; $A+_{region}$, amyloid regionally positive; $A+_{wide}$, amyloid widespread positive; AUC, area under the curve; CDR, clinical dementia rating; CDR-SB, clinical dementia rating sum of boxex; CL, centiloid scale; MMSE mini-mental state examination; PCC, posterior cingulate cortex



	Clinical stage		
	preclinical	MCI	dementia
T_{2-}			1
T_{2MTL+}		1	1
T_{2MOD+}		2	
T_{2HIGH+}		5	1

Figure 2. CSF biomarker results and tau PET using ^{18}F-MK6240 PET

A) All patients with CSF Aβ42/40 ratio above the approved cutoff of 0.067 (A−) showed pTau181 value below the cutoff (56.5 pg/mL) (both in dashed lines). Of the 35 patients with CSF Aβ42/40 below the cutoff, three (8.6%) had values close to the cut-off in the likely-positive range by the US FDA associated with some uncertainties (0.059–0.072) (in dotted lines). These three patients had pTau181 values of 41.0 (< 56.5), 70.8 (56.5–83.1 [in dotted line]), and 89.6 (> 83.1) pg/mL, respectively. Three patients with clearly decreased Aβ42/40 ratio (< 0.059) had pTau181 values in the normal range (< 56.5 pg/mL). The remaining patients had abnormal pTau181 values above (n = 19) or below (n = 13) 83.1 pg/mL. (B) CSF tTau highly correlated with p-tau181 (r = 0.95). (C) Representative tau PET images using ^{18}F-MK6240 PET. Color scales represent the standardized uptake value ratio, with the cerebellum as the reference region (= 1). (D) Tau PET-based Braak stage range from 0 (normal) to VI (max). While one with PET-based Braak stage I had low CSF pTau181, patients with stage V–VI tended to have higher CSF pTau181 values (41.0 vs 109.1 ±32.7 pg/mL, p = 0.13). (E) The assocation between biological stages based on tau PET and clinical stages are presented.

A−, amyloid negative ; A+, amyloid positive; Aβ, amyloid-beta; pTau181, tau phosphorylated at threonine 181; tTau, total tau ; T_{2-}, T2 biomarker negative (no uptake on tau PET); T_{2MTL+}, tau PET uptake restricted to medial temporal areas; T_{2MOD+}, moderate tau PET uptake in the

neocortex; T_{2HIGH+}, high tau PET uptake in the neocortex



Figure 3. Plasma NfL, plasma GFAP, and white matter hyperintensity by Fazekas score

(A, B) Plasma concentrations of NfL and GFAP were compared between A− and A+. While NfL showed no significant difference, GFAP was significantly higher in A+. Plasma NfL and GFAP showed wide distribution from 10.0 to 103.3 pg/mL from 121.9 to 652.5 pg/mL, respectively. In the A+ group, values were grouped in four quartile (Q1, Q2, Q3, Q4) for each biomarker. (C) White matter hyperintensities (V) scored by Fazekas score mainly ranged from 0–2 but included some with maximum 3 both for DWM and PV. (D) The association between plasma NfL, plasma GFAP, Fazekas DWM, and Fazekas PV were highly heterogenous

A−, amyloid negatibe ; A+, amyloid positive; DWM, deep white matter ; GFAP, glial fibrillary acidic protein; NfL, neurofilament light chain; PV, periventicular

	Phase 3 Clarity AD		TMIG	WashU USA (n=234) Paczynski JAMA Neurol 2025	NNI USA (n=71) Shields JPAD 2024	Komodo Data USA (n=3155) Sabbagh Neurol Ther 2025	Veteran USA (n=56) Mittler J Neurol 2025	TLVMC Israel (n=86) Bregman Als Res Ther 2025
	Global (n = 859) van Dyck NEJM 2023	Asia (n = 146) Chen et al. JPAD 2025	This study (1y, n = 93)					
Age	71.4 ±7.9	70.3 ±8.1	74.2 ±8.1	74.4±6.7	72	75.0±6.8	75.9±5.3	72.0±8.2
Sex (female)	51.6%	58.2%	73.1%	50%	62%	55.8%	<10%	53%
MCI	61.5%	69.9%	62.4%		49.3%	60.8%	48.2%	72%
Global CDR 0.5	80.8%	96.6%	88.2%	85%				
CDR-SB	3.17 ±1.34	2.76 ±1.00	2.99 ±1.31					
MMSE	25.5 ±2.2	25.2 ±2.1	24.7 ±2.0	24±4	25			24.0±2.7
Current use of symptomatic	52.0%		41.9%		94%	67.6%	48.2%	
APOE ε4 carrier	68.9%	72.6%	32.4% (12/37)	62.5%	64%			53%
PET centiloid mean	77.9 ±44.8	82.2 ±33.6	59.8 ±24.4					
range	−16.6 to 213		3.1 to 112					

Table 1. Baseline characteristics compared to the phase 3 study and other recent reports of real-world data

Values higher than those of phase 3 study are highlighted in orange, and values lower are highlighted in blue. Compared to the phase 3 study and other real-world data, the characteristics of patient population in this study were high female proportion, low ApoE ε4 carrier rate. Although not reported in other real-world data, amyloid PET centiloid was lower than that reported in the phase 3 trial.

		Amyloid PET (n = 53)				CSF Aβ42/40 (n =35)			
		A+region (n = 11)	A+wide (n = 42)		p value	0.059–0.067 (n = 3)	< 0.059 (n = 32)		p value
Baseline	Age	79.2 ±5.1	73.3 ±8.9	*	0.040	76.7 ±7.4	73.9 ±7.5		0.55
	Female	90.9%	78.6%		0.67	0%	68.8%	*	0.044
	MCI	81.8%	54.8%		0.34	66.7%	59.4%		1
	MMSE	25.5 ±2.2	24.5 ±2.1		0.17	23.3 ±0.58	24.7 ±1.9		0.26
	CDR 0.5	81.8%	81.0%		1	100%	96.9%		1
	CSR-SB	2.68 ±1.38	3.32 ±1.19		0.13	2.17 ±0.76	2.86 ±1.42		0.42
T1	CSF pTau181	n/a	n/a			67.1 ±24.5	98.0 ±36.5		0.16
T2	tau PET-based Braak stage	1 [0.5-1.5]	4 [3.5-4.5]		0.20	1	5 [5-6]		0.21
	available data	2/11	3/42			1/3	5/32		
N	plasma NfL	23.4 ±7.3	29.2 ±20.7		0.40	30.8 ±2.1	20.8 ±6.6	*	0.015
I	plasma GFAP	290 ±148	348 ±125		0.24	264 ±139	312 ±123		0.54
	available data	10/11	29/42			3/3	28/32		
V	Fazekas DWM	1 [1-2]	1 [1-1]	†	0.067	2 [1.5-2]	1 [1-1]		0.13
	Fazekas PV	2 [1-2.5]	1 [1-1]	*	0.022	2 [1.5-2.5]	1 [1-2]		0.19
S	CSF αsyn SAA	n/a	n/a			0%	31.8%		1
	available data					1/3	22/32		

Table 2 Comparison between amyloid PET regional vs widespread positive and CSF Aβ42/40 likely vs clearly positive groups

A+region, amyloid regionally positive; A+wide, amyloid widespread positive; Aβ, amyloid-beta; CDR, clinical dementia rating; CDR-SB, CDR sum of boxes; CSF, cerebrospinal fluid; DWM, deep white matter; GFAP, glial fibrillary acidic protein; MCI, mild cognitive impairment; MMSE, mini-mental state examination; NfL, neurofilament light chain; pTau181, tau phosphorylated at threonine 181; PV, periventricular; SAA, seed amplification assay; αsyn, alpha-synuclein